{"schema_version":"1","generated_at":"2026-11-20T13:48:22.435Z","data_as_of":null,"url":"https://www.findmykol.com/kol/ronnie-luyun","json_url":"https://www.findmykol.com/kol/ronnie-luyun/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"ronnie-luyun","name":"Ronnie Luyun","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"University of Illinois Urbana-Champaign","institution_url":"https://www.findmykol.com/institution/university-of-illinois-urbana-champaign","city":"Urbana","state":"IL","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Ronnie Luyun is an Oncology physician affiliated with University of Illinois Urbana-Champaign. OpenAlex indexes 7 publications with 830 citations (h-index 5).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":7,"cited_by_count":830,"h_index":5,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":19,"program_years":{"first":2021,"last":null},"rows_total":30,"shown":3,"withheld":27,"rows":[{"payer":"Astellas Pharma US Inc","program_year":2025,"amount_usd":99.95,"payment_count":1},{"payer":"PFIZER INC.","program_year":2025,"amount_usd":37.76,"payment_count":2},{"payer":"Eisai Inc.","program_year":2025,"amount_usd":23.6,"payment_count":1}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":12,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":32.3,"classes_total":8,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":10.8,"drugs":[{"name":"Letrozole","share_pct":58},{"name":"Anastrozole","share_pct":37.2},{"name":"Exemestane","share_pct":4.8}],"max_beneficiaries":null},{"class":"Cytochrome P450 17A1 Inhibitor","setting":"prescribed","share_pct":9.6,"drugs":[{"name":"Abiraterone Acetate","share_pct":100}],"max_beneficiaries":27}]},{"area":"Nervous system","share_pct":22.5,"classes_total":7,"classes":[{"class":"Opioid Agonist","setting":"prescribed","share_pct":7.9,"drugs":[{"name":"Oxycodone Hcl","share_pct":51.5},{"name":"Morphine Sulfate Er","share_pct":17.8},{"name":"Oxycodone-Acetaminophen","share_pct":16},{"name":"Fentanyl","share_pct":7.7},{"name":"Oxycontin","share_pct":7.1}],"max_beneficiaries":null},{"class":"Phenothiazine","setting":"prescribed","share_pct":6.4,"drugs":[{"name":"Prochlorperazine Maleate","share_pct":100}],"max_beneficiaries":89}]},{"area":"Metabolism & gastrointestinal","share_pct":22.1,"classes_total":7,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":9.2,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":45},{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":4.1,"drugs":[{"name":"Ondansetron Hcl","share_pct":86.4},{"name":"Ondansetron Odt","share_pct":13.6}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2023,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":7,"shown":5,"withheld":2,"matched_by":"OpenAlex author record","recent":[{"title":"Waxing and Waning Lymphadenopathy","year":2013,"journal":"The American Journal of Medicine","source_url":"https://doi.org/10.1016/j.amjmed.2013.01.009","status":"verified"},{"title":"Brief Report: A Phase II “Window-of-Opportunity” Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an NCCTG Study","year":2012,"journal":"Journal of Thoracic Oncology","source_url":"https://doi.org/10.1097/jto.0b013e31824de0d6","status":"verified"},{"title":"A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9)","year":2009,"journal":"Lung Cancer","source_url":"https://doi.org/10.1016/j.lungcan.2009.06.020","status":"verified"},{"title":"A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study","year":2007,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2007.25.18_suppl.7547","status":"verified"},{"title":"Anti-tumor activity of mTOR inhibitor temsirolimus for relapsed mantle cell lymphoma: A phase II trial in the North Central Cancer Treatment Group","year":2006,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2006.24.18_suppl.7532","status":"verified"}],"source":"works"},"similar":[{"name":"Jalees Rehman","slug":"jalees-rehman","institution":"University of Illinois Urbana-Champaign","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/jalees-rehman","json_url":"https://www.findmykol.com/kol/jalees-rehman/profile.json"},{"name":"Jie Chen","slug":"jie-chen-us","institution":"University of Illinois Urbana-Champaign","url":"https://www.findmykol.com/kol/jie-chen-us","json_url":"https://www.findmykol.com/kol/jie-chen-us/profile.json"},{"name":"Chris Ka Pun Mok","slug":"chris-mok","institution":"University of Illinois Urbana-Champaign","url":"https://www.findmykol.com/kol/chris-mok","json_url":"https://www.findmykol.com/kol/chris-mok/profile.json"},{"name":"James Egner","slug":"james-egner","institution":"University of Illinois Urbana-Champaign","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/james-egner","json_url":"https://www.findmykol.com/kol/james-egner/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":27,"publications":2}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}